Gudrun Bachmann
Chief Technology OfficerMs. Gudrun Bachmann, Ph.D., is Chief Technology Officer of Oculis Holding AG from September 2024. Ms. Bachmann Gudrun joined Oculis in February 2022 as Senior Vice President of CMC (Chemistry, Manufacturing and Controls). Prior to joining Oculis, she spent 4 years with Fresenius Kabi in Switzerland initially as Director, Head of CMC Program Leads from 2018 to 2020 and later as Senior Director, Global Head of CMC Leads from 2020 to 2022. From 2014 and 2018, she held various drug development and manufacturing roles for Alvotec in Iceland including Director, Head of Drug Product Biopharmaceutical Development from 2015 to 2016 and Head of Drug Product Biopharmaceutical Development & Manufacturing from 2016 to 2018. She began her career with Sandoz as a Scientist from 2011 to 2012 and Lab Head, Late-Stage Biopharmaceutical Development from 2012 to 2014. Ms. Bachmann holds a Ph.D. in Structural Biology & Biochemistry from the Institute of Cancer Research and an M.Sc. in Biotechnology Engineering from Aalborg University.
Positions
- Company NameOculis Holding AGStock CodeOCSPositionChief Technology OfficerRelated SecuritiesColleagues
- RSRiad SherifCEO & Director
- AAAnthony A. RosenbergIndependent Chairman
- SCSylvia CheungChief Financial Officer
- BTBjorn TackenbergChief Scientific Officer
- KAKatie A. KazemChief Legal & Compliance Officer
- AMArshad M. KhananiChair of Retina Scientific Advisory Board & Independent Director
- GOGeraldine O'KeeffeIndependent Director
- EDEric D. DonnenfeldChair of Cornea Scientific Advisory Board
